1. Home
  2. Stocks
  3. Tatva Share Price

Tatva Chintan Pharma Chem Share Price

Chemicals Small Cap

₹856.80 +0.45 (0.05%)

05 Nov, 2024 17:28

SIP TrendupStart SIP in TATVA

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹849
  • High
  • ₹866
  • 52 Week Low
  • ₹789
  • 52 Week High
  • ₹1,651
  • Open Price₹861
  • Previous Close₹856
  • Volume22,198

Investment Returns

  • Over 1 Month -15.08%
  • Over 3 Month -13.79%
  • Over 6 Month -31.11%
  • Over 1 Year -39.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Tatva Chintan Pharma Chem for Steady Growth!

Tatva Chintan Pharma Chem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 113.8
  • PEG Ratio
  • -1.8
  • Market Cap Cr
  • 2,004
  • P/B Ratio
  • 2.7
  • Average True Range
  • 38.51
  • EPS
  • 12.6
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -33.15
  • RSI
  • 37.61
  • MFI
  • 23.54

Tatva Chintan Pharma Chem Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations80.9693.8193.9386.0792.57
Total Income From Operations80.9693.8193.9386.0792.57
P/L Before Interest, Excpt. Items & Tax-1.412.4512.496.9414.72
P/L Before Exceptional Items & Tax-1.582.1412.286.5611.71
P/L After Tax from Ordinary Activities-1.111.518.254.658.20
Net Profit/Loss For the Period-1.111.518.254.658.20
IndicatorMar 24Mar 23
Revenue From Operations [Gross]375.67400.32
Revenue From Operations [Net]375.67400.32
Total Operating Revenues378.68403.04
Total Revenue386.19408.72
Total Expenses343.92366.30
Profit/Loss Before Tax42.2738.83
Profit/Loss For The Period29.3540.47
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity102.7823.73
Net Cash Used In Investing Activity-120.54-101.12
Net Cash Used in Finance Activity30.5437.82
Net Inc/Dec In Cash And Equivalent12.80-39.59
Cash And Equivalent End Of Year33.9921.19
IndicatorMar 24Mar 23
Total Share Capital23.3922.17
Total Non-Current Liabilities1.975.38
Total Current Liabilities87.21244.70
Total Capital And Liabilities815.07754.86
Total Non-Current Assets521.46443.39
Total Current Assets293.61311.47
Total Assets815.07754.86
Indicator20242023
EBIT Margin (%)12.8712.60
Return On Capital Employed (%)6.709.95
Return On Equity (%)4.048.01
Long Term Debt To Equity (%)0.080.83
Book Value/Share (INR)310.31227.74
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations83.49105.4698.2784.2196.67
Total Income From Operations83.49105.4698.2784.2196.67
P/L Before Interest, Excpt. Items & Tax-0.857.1213.905.6214.23
P/L Before Exceptional Items & Tax-1.026.8113.695.2411.21
P/L After Tax from Ordinary Activities-0.665.219.613.467.78
Net Profit/Loss For the Period-0.665.219.613.467.78
IndicatorMar 24Mar 23
Revenue From Operations [Gross]390.50420.89
Revenue From Operations [Net]390.50420.89
Total Operating Revenues393.50423.61
Total Revenue401.01429.36
Total Expenses357.45380.99
Profit/Loss Before Tax43.5744.78
Profit/Loss For The Period30.3545.49
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity98.0427.78
Net Cash Used In Investing Activity-120.54-101.14
Net Cash Used in Finance Activity30.5237.80
Net Inc/Dec In Cash And Equivalent7.94-35.65
Cash And Equivalent End Of Year35.3027.37
IndicatorMar 24Mar 23
Total Share Capital23.3922.17
Total Non-Current Liabilities1.975.38
Total Current Liabilities79.66236.13
Total Capital And Liabilities818.72756.30
Total Non-Current Assets520.81442.75
Total Current Assets297.91313.56
Total Assets818.72756.30
Indicator20242023
EBIT Margin (%)12.7313.40
Return On Capital Employed (%)6.7710.91
Return On Equity (%)4.118.83
Long Term Debt To Equity (%)0.080.82
Book Value/Share (INR)315.10232.25

Tatva Chintan Pharma Chem Technicals

EMA & SMA

Current Price
₹856.80
+ 0.45 (0.05%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹915.11
  • 50 Day
  • ₹963.79
  • 100 Day
  • ₹1,016.87
  • 200 Day
  • ₹1,134.98

Resistance and Support

861.17 Pivot Speed
  • R3 895.13
  • R2 885.42
  • R1 870.88
  • S1 846.63
  • S2 836.92
  • S3 822.38

Is Tatva Chintan Pharma Chem Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Tatva Chintan Pharma manufactures specialty chemicals, including phase transfer catalysts, pharmaceutical intermediates, and electrolytes for batteries. With global operations and R&D capabilities, it serves industries like pharmaceuticals, agrochemicals, and automotive, providing innovative chemical solutions. Tatva Chintan Pharma Chem has an operating revenue of Rs. 371.43 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of 11% is healthy, ROE of 4% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 21 which is a POOR score indicating inconsistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 126 indicates it belongs to a poor industry group of Chemicals-Basic and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Tatva Chintan Pharma Chem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-24 Quarterly Results
2024-05-03 Audited Results & Final Dividend
2024-01-20 Quarterly Results
2023-11-02 Quarterly Results
Date Purpose Remarks
2022-09-09 FINAL Rs.2.00 per share(20%)Final Dividend

Tatva Chintan Pharma Chem F&O

Tatva Chintan Pharma Chem Shareholding Pattern

72.02%
6.76%
3.33%
15.95%
1.94%
  • NSE Symbol
  • TATVA
  • BSE Symbol
  • 543321
  • Chairman & Managing Director
  • Mr. Chintan Nitinkumar Shah
  • ISIN
  • INE0GK401011

Tatva Chintan Pharma Chem FAQs

Tatva Chintan Pharma Chem share price is ₹856 As on 05 November, 2024 | 17:14

The Market Cap of Tatva Chintan Pharma Chem is ₹2004.2 Cr As on 05 November, 2024 | 17:14

The P/E ratio of Tatva Chintan Pharma Chem is 113.8 As on 05 November, 2024 | 17:14

The PB ratio of Tatva Chintan Pharma Chem is 2.7 As on 05 November, 2024 | 17:14

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.